{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diverticular-disease/prescribing-information/ciprofloxacin/","result":{"pageContext":{"chapter":{"id":"463ca371-3542-5765-8350-4a0a640f0cae","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin","depth":2,"htmlHeader":"<!-- begin field ae36346d-e7f7-4e71-8c98-d6a158c4d85a --><h2>Ciprofloxacin</h2><!-- end field ae36346d-e7f7-4e71-8c98-d6a158c4d85a -->","summary":"","htmlStringContent":"<!-- begin item 7690df0f-e5be-49a6-8d1f-37f820e79c52 --><!-- end item 7690df0f-e5be-49a6-8d1f-37f820e79c52 -->","topic":{"id":"94c44346-c791-5b97-9e45-bacb8fe90589","topicId":"eee234d5-c667-4944-95d2-a45f5e032286","topicName":"Diverticular disease","slug":"diverticular-disease","lastRevised":"Last revised in January 2021","chapters":[{"id":"5bcd7ed5-7ab4-57a1-a517-99ee8bb7b2d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5abc06b8-fef4-5d67-81ce-ee1c71284864","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"71ba91f6-898b-5f69-bd52-93f3b1892ad6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7460514b-3977-52be-9e12-06486604b194","slug":"changes","fullItemName":"Changes"},{"id":"909831b0-6f3c-5e85-8263-a5e1785b8a49","slug":"update","fullItemName":"Update"}]},{"id":"fcd203c7-5d1a-5fcc-ab90-5286ab76bd2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2cbe6fe5-f942-566e-9136-915145ba8517","slug":"goals","fullItemName":"Goals"},{"id":"ffcabc25-6966-526d-8382-a5fcf56185ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"dc0b24e2-e0db-5829-baf5-a7aae6d5ab67","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b5dcfe41-ec7c-5a9f-bc96-229f8b818a77","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d9311147-ff58-5778-bb86-c0249937ef45","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b76632c-4924-5c26-99ab-549b62bb2f73","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"435ea69d-fb08-554b-b803-cc64d393575b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"12666ff2-dbf6-51be-b83a-78c0d4aa12e3","slug":"definition","fullItemName":"Definition"},{"id":"3a4412ce-ae17-58e7-8460-9ab759755b96","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"11908cbc-fb2b-525e-9bed-e9da60b6ad8a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2efdd449-ac81-531a-9514-72e57632cf72","slug":"complications","fullItemName":"Complications"},{"id":"2bb98737-1604-5f47-8f96-27003159f003","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b9740a9c-8383-57e1-8cc6-7fea164147c7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"411e61cd-aad7-5e40-bf27-38061aae07cb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"21f90600-3a9d-5e53-92e4-7305f17db5aa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c90663d3-95e7-5f18-9718-27a43a51abbf","fullItemName":"Management","slug":"management","subChapters":[{"id":"43142f56-faaf-50dc-a1b7-1d4fb26d1a5e","slug":"diverticulosis","fullItemName":"Scenario: Diverticulosis"},{"id":"a1baccf2-7945-577b-b755-eff86d33201c","slug":"diverticular-disease","fullItemName":"Scenario: Diverticular disease"},{"id":"0c23dfbe-5e71-5eeb-9b03-6b3377f49225","slug":"acute-diverticulitis","fullItemName":"Scenario: Acute diverticulitis"}]},{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2bc84877-2507-5c10-af40-fef065820ce1","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"ba178fdc-1c2f-58e1-aec7-b1f903ed5207","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"524ca556-9a60-542a-9102-901470ef4882","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"463ca371-3542-5765-8350-4a0a640f0cae","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"231102c0-511c-5785-ac06-8720d28571cb","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f2cde7d6-3b3a-5b9f-bf9c-9c7445a1ae6f","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"8b942243-eed9-557a-9678-01f6c77e2b91","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ccd6405-b8ec-557d-9d70-bce3f43accbd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"544db73d-5bf7-5ac9-81f4-784210ec7343","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2fb4d8d-7ad7-55ef-837b-a9faa80ba34d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8cbe5c96-baf1-5b25-af5c-6f36a3d9ea3c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7518d3a3-e804-5074-908b-2b9f984cbf60","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e84d6049-8652-59d8-a02d-c49972295f21","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1de75d4a-a4c8-5742-add9-eabcb6711bcb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"369d8ea3-4368-5744-806a-a5deddd5443e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4d84a6f1-5b2b-43e8-9e47-fda3aa4f56e3 --><h3>Contraindications and cautions</h3><!-- end field 4d84a6f1-5b2b-43e8-9e47-fda3aa4f56e3 -->","summary":"","htmlStringContent":"<!-- begin item 64e02f4b-ecc9-46bf-9d3e-1c00542fc80c --><!-- begin field 674d4064-f20b-4cc8-bd8f-2949aff6e959 --><ul><li><strong>Do not prescribe ciprofloxacin to people:</strong><ul><li>With a history of tendon disorders related to quinolone use.</li><li>Who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic.</li><li>Taking a corticosteroid — coadministration could exacerbate fluoroquinolone-induced tendonitis and tendon rupture.</li></ul></li><li><strong>Prescribe ciprofloxacin with caution to people with:</strong><ul><li>Aortic aneurysm and/or aortic dissection, a family history of aneurysm disease, or with risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis).</li><li>Epilepsy, or conditions that predispose to seizures, and in people taking other medication that may predispose to seizures, as quinolones can lower the seizure threshold.<ul><li>Quinolones may induce convulsions in patients with or without a history of convulsions, and taking NSAIDs at the same time may also induce them.</li></ul></li><li>Diabetes mellitus — may affect blood glucose. Blood glucose should be monitored closely.</li><li>Glucose-6-phosphate dehydrogenase deficiency —haemolytic reactions have been reported.</li><li>A history of tendonitis — quinolones can very rarely cause tendon damage, and the risk of tendon rupture is increased by co-administration of corticosteroid.</li><li>Conditions which predispose to QT interval prolongation:<ul><li>Congenital long QT syndrome.</li><li>Concomitant use of drugs that are known to prolong the QT interval (for example Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (for example hypokalaemia, or hypomagnesaemia).</li><li>Cardiac disease (for example, heart failure, myocardial infarction, or bradycardia).</li><li>Electrolyte disturbances.</li></ul></li><li>History of a psychotic disorder — there have been reports of suicidal thoughts or self-endangering behaviour after use quinolones. </li><li>Myasthenia gravis — symptoms can be exacerbated.</li></ul></li><li>Also prescribe with caution in people aged over 60 years, people with renal impairment or solid-organ transplants, as they are at a higher risk of tendon injury.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">MHRA, 2019</a>]</p><!-- end field 674d4064-f20b-4cc8-bd8f-2949aff6e959 --><!-- end item 64e02f4b-ecc9-46bf-9d3e-1c00542fc80c -->","subChapters":[]},{"id":"39440019-6246-51bc-a967-98d8629a86b5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 89e5e31f-22d4-4405-b153-3de71f76a19d --><h3>Adverse effects</h3><!-- end field 89e5e31f-22d4-4405-b153-3de71f76a19d -->","summary":"","htmlStringContent":"<!-- begin item 56dff518-2ac4-4ec0-b7f2-5dda721adb51 --><!-- begin field ac043a1e-5b4d-4bc3-b097-1581cc9c67cc --><ul><li><strong>Gastrointestinal </strong>— diarrhoea, nausea (common), vomiting, dyspepsia, flatulence, gastrointestinal and abdominal pains (uncommon).<ul><li><strong>Rarely</strong>: pseudomembranous colitis (for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>).</li></ul></li><li><strong>Musculoskeletal </strong>— pain, arthralgia (uncommon).<ul><li><strong>Rarely:</strong> myalgia, arthritis.</li><li><strong>Very rarely</strong>: muscle weakness, tendonitis, tendon damage — this may occur within 48 hours of starting treatment, or months after stopping. Risk of tendon rupture is increased by co-administration of corticosteroids and in people aged over 60 years. If tendonitis is suspected, ciprofloxacin should be discontinued immediately.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness, sleep disorders, taste disorders (uncommon).<ul><li><strong>Rarely</strong>: tremor, vertigo, lowering of the seizure threshold – this may trigger seizures. </li></ul></li><li><strong>Psychiatric</strong> — hyperactivity, agitation (uncommon).<ul><li><strong>Rarely</strong>: confusion, anxiety, depression, hallucinations.</li></ul></li><li><strong>Skin</strong> — rash, pruritus, urticaria.<ul><li><strong>Rarely: </strong>Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis anaphylaxis, drug rash with eosinophilia, systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP).</li></ul></li><li><strong>Cardiovascular system</strong> — there is an increased risk of aortic aneurysm and dissection with fluoroquinolones, particularly in the older population. Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in people with positive family history of aneurysm disease, or in people diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet’s disease, hypertension, known atherosclerosis).</li><li><strong>Other adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Hepatic impairment, hepatitis.</li><li>Renal impairment.</li><li>Tachycardia.</li><li>Tinnitus.</li><li>Visual disturbances.</li></ul></li><li><strong>NOTE: </strong>fluoroquinolones can very rarely cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses. People should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendonitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">MHRA, 2019</a>]</p><!-- end field ac043a1e-5b4d-4bc3-b097-1581cc9c67cc --><!-- end item 56dff518-2ac4-4ec0-b7f2-5dda721adb51 -->","subChapters":[]},{"id":"89eea529-0e3f-5a4c-b21f-b6dd338dcb54","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 48c16c0b-4c1d-4112-92e7-a7b300dcae4e --><h3>Drug interactions</h3><!-- end field 48c16c0b-4c1d-4112-92e7-a7b300dcae4e -->","summary":"","htmlStringContent":"<!-- begin item 6af68a3c-c95a-4174-a0d0-a7b300dcac25 --><!-- begin field 351109b5-ec75-43c9-884e-a7b300dcae4e --><ul><li><strong>Antacids (containing aluminium, calcium, or magnesium) and other medications containing iron or zinc </strong>— these reduce the absorption of ciprofloxacin if taken concurrently.<ul><li>Ciprofloxacin should be taken at least 2 hours before these preparations, and not less than 4 to 6 hours after them.</li></ul></li><li><strong>Ciclosporin</strong> — increased concentrations and nephrotoxicity might occur in a small number of patients.</li><li><strong>Corticosteroids</strong> — the risk of tendonitis and tendon rupture is increased in people taking a fluoroquinolone and a corticosteroid. The MHRA advises that concurrent should be avoided. </li><li><strong>Domperidone</strong> — the manufacturer advises that concurrent use with ciprofloxacin should be avoided as it may lead to QT interval prolongation.</li><li><strong>Ergometrine </strong>— levels may be increased, leading to ergotism. Concurrent use is contraindicated. </li><li><strong>Mizolastine</strong> — the manufacturer advises that concurrent use should be avoided. Mizolastine has a weak potential to cause QT interval prolongation in some people and this may be additive to the effects of ciprofloxacin.</li><li><strong>Methotrexate</strong> — plasma levels of methotrexate may be increased. The manufacturer recommends that concurrent use is avoided.<ul><li>If concurrent use is necessary, monitor methotrexate levels.</li></ul></li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of ciprofloxacin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Phenytoin</strong> — concurrent administration of ciprofloxacin can cause an increase or decrease in serum phenytoin levels. Monitor phenytoin levels.</li><li><strong>Strontium ranelate </strong>— the absorption of quinolones is reduced by strontium ranelate so they should not be given together.</li><li><strong>Theophylline </strong>— ciprofloxacin increases the plasma concentration of theophylline, leading to possible increased risk of convulsions. Monitor theophylline concentration closely.</li><li><strong>Tizanidine </strong>— ciprofloxacin increases the plasma concentration of tizanidine (increased risk of toxicity). Avoid conccurrent use.</li><li><strong>Warfarin </strong>— rarely, ciprofloxacin may enhance the anticoagulant effect, increasing the risk of bleeding. Monitor the international normalised ratio (INR) within 3 to 5 days of starting ciprofloxacin, frequently during and shortly after administration.</li><li><strong>Zolmitriptan </strong>— quinolones increase the plasma concentration of zolmitriptan by inhibiting its metabolism. Manufacturer recommends a maximum dose of 5 mg in 24 hours in people taking a quinolone.</li><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">MHRA, 2019</a>]  </p><!-- end field 351109b5-ec75-43c9-884e-a7b300dcae4e --><!-- end item 6af68a3c-c95a-4174-a0d0-a7b300dcac25 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}